Compare GGT & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GGT | ALEC |
|---|---|---|
| Founded | 1994 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.5M | 262.7M |
| IPO Year | N/A | 2019 |
| Metric | GGT | ALEC |
|---|---|---|
| Price | $4.02 | $2.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.83 |
| AVG Volume (30 Days) | 274.9K | ★ 743.0K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 15.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $45.24 |
| P/E Ratio | $4.93 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.75 | $0.87 |
| 52 Week High | $4.94 | $3.40 |
| Indicator | GGT | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 40.05 | 55.09 |
| Support Level | $3.94 | $1.22 |
| Resistance Level | $4.29 | $2.55 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 1.89 | 50.00 |
Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.